NCT03757767

Brief Summary

Elevated levels of plasma triglycerides are increasingly recognized as an important causal risk factor for cardiovascular disease and associated pathologies. Lowering plasma triglycerides may therefore be a therapeutic target to lower cardiovascular disease risk. With this study the investigators want to examine the effects of fasting on adipose tissue metabolism in humans.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2018

Completed
3 days until next milestone

Study Start

First participant enrolled

November 12, 2018

Completed
17 days until next milestone

First Posted

Study publicly available on registry

November 29, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 22, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 22, 2019

Completed
Last Updated

April 24, 2019

Status Verified

April 1, 2019

Enrollment Period

2 months

First QC Date

November 9, 2018

Last Update Submit

April 23, 2019

Conditions

Keywords

PhysiologyHumans

Outcome Measures

Primary Outcomes (4)

  • Change in ANGPTL4 protein and gene expression in adipose tissue

    Using Western blotting, the change in ANGPTL4 protein expression in adipose tissue will be measured from fed to a prolonged fasted state. The change in ANGPTL4 gene expression in adipose tissue will be measured from fed to a prolonged fasted state using whole genome affymetrix microarrays and targeted quantitative real time PCR.

    there are 24 hours between the measurement in de fed and the fasted state

  • Change in LPL expression, both gene and protein, and LPL activity in adipose tissue

    Using Western blotting, the change in LPL protein expression in adipose tissue will be measured from fed to a prolonged fasted state. The change in LPL gene expression in adipose tissue will be measured from fed to a prolonged fasted state using whole genome affymetrix microarrays and targeted quantitative real time PCR. The change in LPL activity in subcutaneous adipose tissue will be measured from fed to a prolonged fasted state, using a lipoprotein lipase assay.

    There are 24 hours between the measurement in the fed and the fasted state

  • Change in ANGPTL4 expression in plasma

    Using ELISA, the change in ANGPTL4 expression in plasma will be measured from fed to a prolonged fasted state.

    There are 24 hours between the measurement in the fed and the fasted state

  • Change in ANGPTL4 and LPL gene expression in PBMCs

    The change in ANGPTL4 and LPL gene expression in PBMCs from fed to a prolonged fasted state will be measured using whole genome affymetrix microarrays and targeted quantitative real time PCR.

    There are 24 hours between the measurement in the fed and the fasted state

Secondary Outcomes (4)

  • Change in whole genome expression

    There are 24 hours between the measurement in the fed and the fasted state

  • Post-transcriptional changes

    There are 24 hours between the measurement in the fed and the fasted state

  • Changes in metabolite profiles

    There are 24 hours between the measurement in the fed and the fasted state

  • Changes in protein profiles

    There are 24 hours between the measurement in the fed and the fasted state

Other Outcomes (1)

  • BMI

    At baseline

Study Arms (1)

Intervention arm

EXPERIMENTAL

Fasting for 26-hours.

Other: Fasting for 26-hours

Interventions

All research subjects will have to fast for 26 hours in total. All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points.

Also known as: Prolonged fasting
Intervention arm

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Apparently healthy man or woman
  • Age 40-70y at the time of recruitment
  • BMI of 22-30 kg/m2
  • Willing to fast for 26 hours
  • Willing to give blood samples
  • Willing to give adipose tissue biopsies
  • Willing to consume the standardized meal on test day 1
  • Signed informed consent
  • Having a general practitioner

You may not qualify if:

  • Alcohol on average: more than 2 consumptions/day or more than 14 consumptions/week
  • Tobacco smoker
  • Usage of drugs
  • Following a diet within one month of starting the study (for example a ketogenic diet)
  • Allergic to one or more components of the standardized meal
  • Donated or intend to donate blood from 2 months before the study until the end of the study
  • Unstable body weight (weight gain or loss \>5 kg in the past three months)
  • Diagnosed with any long-term medical condition that can interfere with the study outcome (i.e. cardiovascular disease, diabetes mellitus type 1 or 2, liver, pulmonary, or renal disease)
  • Use of prescribed medication
  • Use of supplements or over the counter medication (OTC) known to interfere with glucose or lipid homeostasis in the week before the start of the study, and during the study
  • Being pregnant or lactating
  • Participation in another biomedical study (other than the EetMeetWeet study) during this study
  • Members of the research team, or first degree family members of the research team
  • Working, or doing an internship at the division "Human Nutrition and Health" - Wageningen University

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wageningen University, Division of Human Nutrition

Wageningen, Gelderland, 6700 EV, Netherlands

Location

Related Publications (1)

  • Ruppert PMM, Michielsen CCJR, Hazebroek EJ, Pirayesh A, Olivecrona G, Afman LA, Kersten S. Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue. Mol Metab. 2020 Oct;40:101033. doi: 10.1016/j.molmet.2020.101033. Epub 2020 Jun 3.

MeSH Terms

Conditions

Fasting

Condition Hierarchy (Ancestors)

Feeding BehaviorBehavior

Study Officials

  • Lydia Afman, PhD

    Wageningen University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Model Details: Research subjects are measured in the fed state and in the prolonged fasted state.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 9, 2018

First Posted

November 29, 2018

Study Start

November 12, 2018

Primary Completion

January 22, 2019

Study Completion

January 22, 2019

Last Updated

April 24, 2019

Record last verified: 2019-04

Locations